Anja Vogt

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 305 citations · Full text

Public Health, Endocrinology, Genetics +13

Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months

Axel Schmermund, Stephan Achenbach, Thomas Budde et al. · Circulation · 2006 · 254 citations · Full text

Medicine, Cardiology, Pharmacology +17

Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study)

Christie M. Ballantyne, Robert Weiss, Tiziano Moccetti et al. · The American Journal of Cardiology · 2007 · 196 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Patrick M. Moriarty, Klaus G. Parhofer, Stephan P. Babirak et al. · European Heart Journal · 2016 · 196 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?

Adrian Rosada, Ursula Kassner, Anja Vogt et al. · Artificial Organs · 2013 · 82 citations

Medicine, Cardiology, Clinical Cardiology +15